Stifel Nicolaus analyst Mathew Blackman maintained a Buy rating on Senseonics Holdings (SENS – Research Report) today and set a price target of $2.50. The company’s shares closed yesterday at $0.44.
According to TipRanks, Blackman is a 4-star analyst with an average return of 14.9% and a 51.09% success rate. Blackman covers the Healthcare sector, focusing on stocks such as Tandem Diabetes Care, Globus Medical, and Alphatec Holdings.
Currently, the analyst consensus on Senseonics Holdings is a Moderate Buy with an average price target of $2.25.
SENS market cap is currently $235.8M and has a P/E ratio of -4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Senseonics Holdings (SENS) Company Description:
Senseonics Holdings, Inc. engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its primary product is the brand Eversense, a gluscose monitoring device which includes sensor, smart transmitter, and mobile application. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.
Read More on SENS:
- Options Volatility and Implied Earnings Moves Today, May 13, 2024
- Options Volatility and Implied Earnings Moves This Week, May 13 – May 16, 2024
- Senseonics Holdings Inc. (SENS) Q1 Earnings Cheat Sheet
- Senseonics Eversense granted integrated CGM designation by FDA
- Senseonics Board Shift: Schumm Out, Hansen In Until 2025
